Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00447577 · ClinicalTrials.gov registry record · Phase 4
Zylet vs TobraDex in Blepharokeratoconjunctivitis
A Phase 4 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 4
- Development phase
- 276
- Enrollment target
NCT00447577 is a Phase 4 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 276 participants.
The verdict
NCT00447577, a Phase 4 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 276 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and efficacy of Zylet vs. Tobradex in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis
Interventions
- DRUG Loteprednol etabonate and tobramycin ophthalmic suspension
- DRUG Tobramycin and dexamethasone ophthalmic suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2007-01 |
| Est. Completion | 2007-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00447577
The ClinicalTrials.gov registry entry for NCT00447577 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Loteprednol etabonate and tobramycin ophthalmic suspension is the first listed.
NCT00447577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00447577 about?
NCT00447577 is a clinical study titled "Zylet vs TobraDex in Blepharokeratoconjunctivitis". The objective of this study is to evaluate the safety and efficacy of Zylet vs. Tobradex in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis
What is the current status of trial NCT00447577?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 276 participants. The study started on 2007-01. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00447577?
The interventions under investigation include: Loteprednol etabonate and tobramycin ophthalmic suspension (DRUG), Tobramycin and dexamethasone ophthalmic suspension (DRUG).
Who is sponsoring clinical trial NCT00447577?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.